ARTICLE | Product Development
LAG3 to steal the spotlight from TIGIT at ASCO21
BMS shares the first pivotal efficacy data for a next-generation checkpoint inhibitor
May 19, 2021 10:02 PM UTC
For the second year in a row, next-generation checkpoints are stealing the show at ASCO, and new data from this year’s standout target — LAG3 — are positioning the T cell receptor to become the first new checkpoint to reach registration in more than six years.
The 2021 American Society of Clinical Oncology (ASCO) virtual conference is set to deliver promising readouts for several compounds targeting LAG3 including data from Bristol Myers Squibb Co. (NYSE:BMY) that could lead to the first registrational filing for a next-generation checkpoint blocker. ...